Search
Now showing items 1-10 of 10
Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study
(2023-09-21)
Background and objectives:
Alemtuzumab demonstrated superior efficacy versus subcutaneous interferon (IFN) beta-1a in participants with relapsing-remitting multiple sclerosis in the 2-year CARE-MS I and II trials. Efficacy ...
A plain language summary of what clinical studies can tell us about the safety of evobrutinib – a potential treatment for multiple sclerosis
(2023-08)
What is this summary about?: This summary explains the findings from a recent investigation that combined the results of over 1000 people from three clinical studies to understand the safety of evobrutinib. Evobrutinib is ...
Clinical use of dimethyl fumarate in multiple sclerosis treatment: an update to include China, using a modified Delphi method
(2023-07-14)
Dimethyl fumarate (DMF) is a widely used oral disease-modifying therapy for multiple sclerosis (MS). Its efficacy and safety profiles are supported by over a decade of experience. Differences exist between Asia and ...
Views of Multiple Sclerosis Patients About Key Elements for a Decision Aid: A Qualitative Study
(2023-10)
BACKGROUND: Patients with multiple sclerosis (MS) may experience decisional conflict during treatment choice. Shared decision making (SDM), whereby patients and health professionals, primarily nurses, collaborate in making ...
Liquid Biopsy in Neurological Diseases
(2023-07-22)
The most recent and non-invasive approach for studying early-stage biomarkers is liquid biopsy. This implies the extraction and analysis of non-solid biological tissues (serum, plasma, saliva, urine, and cerebrospinal ...
Diagnostic challenge in children with an acquired demyelinating syndrome: an illustrative case report
(2023-07-20)
The clinical-radiological and biological overlap of the spectrum of pediatric demyelinating disorders makes the diagnostic process of a child with an acquired demyelinating syndrome truly challenging. We present a 9-year-old ...
Effect of Evobrutinib on Slowly Expanding Lesion Volume in Relapsing Multiple Sclerosis: A Post Hoc Analysis of a Phase 2 Trial
(2024-03-12)
Background and Objectives
Chronic active lesions (CALs) are demyelinated multiple sclerosis (MS) lesions with ongoing microglia/macrophage activity, resulting in irreversible neuronal damage and axonal loss. Evobrutinib ...
Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study
(2023-12)
Background:
Multiple sclerosis (MS) negatively affects health-related quality of life (HRQoL).
Objective:
To evaluate HRQoL in people with highly active relapsing MS treated with cladribine tablets (CladT; 3.5 mg/kg ...
Vaccine Safety and Immunogenicity in Patients With Multiple Sclerosis Treated With Natalizumab
(2024-04-01)
Importance Vaccination in patients with highly active multiple sclerosis (MS) requiring prompt treatment initiation may result in impaired vaccine responses and/or treatment delay.
Objective To assess the immunogenicity ...